Myasthenia gravis (MG) is an autoimmune neuromuscular disorder that leads to fluctuating fatigability and weakness, which is mediated by circulating antibodies against postsynaptic membrane proteins, such as antibodies against acetylcholine receptor (AChR), muscle-specific kinase (MuSK), and low-density lipoprotein receptor (LRP4) (1). This evidence concerns the gene LDLR and myasthenia gravis.